Published in Blood on May 05, 2009
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol (2011) 1.79
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood (2015) 1.39
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 1.36
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle (2012) 1.12
Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother (2012) 1.10
Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest (2010) 1.10
Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res (2014) 1.09
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood (2013) 1.07
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol (2012) 0.97
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J (2012) 0.97
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97
Tolerance: an overview and perspectives. Nat Rev Nephrol (2010) 0.95
Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol (2012) 0.95
PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol Ther (2012) 0.93
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood (2015) 0.93
Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One (2012) 0.92
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol (2013) 0.91
Blocking PD-1 in cancer immunotherapy. Blood (2009) 0.90
Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J (2014) 0.89
Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol (2015) 0.89
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J (2015) 0.87
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J (2011) 0.86
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid (2014) 0.85
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. J Clin Cell Immunol (2012) 0.85
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One (2014) 0.84
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol (2014) 0.83
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica (2013) 0.83
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res (2014) 0.83
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol (2012) 0.82
Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer (2017) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica (Cairo) (2012) 0.80
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol (2016) 0.80
Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther (2015) 0.79
CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. J Hematol Oncol (2016) 0.79
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget (2016) 0.78
MicroRNA-29b mediates altered innate immune development in acute leukemia. J Clin Invest (2016) 0.78
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch (2016) 0.78
Peripheral T-cell tolerance in hosts with acute myeloid leukemia. Oncoimmunology (2013) 0.78
Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med Chem (2010) 0.78
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep (2016) 0.78
An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS One (2015) 0.78
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget (2016) 0.78
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther (2011) 0.78
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol (2016) 0.78
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology (2015) 0.76
T-cell Exhaustion and Cancer Immunotherapy. J Int Oral Health (2015) 0.75
Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia. Blood Cancer J (2015) 0.75
Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol (2015) 0.75
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget (2017) 0.75
Specificity may be overrated in cancer immunotherapy: Getting to know the nonspecific side of memory T Cells. Oncoimmunology (2012) 0.75
Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget (2016) 0.75
Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets (2015) 0.75
Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica (2016) 0.75
Novel therapeutic options in Acute Myeloid Leukemia. Leuk Res Rep (2016) 0.75
Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology (2017) 0.75
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer (2016) 0.75
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med (2017) 0.75
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. Oncoimmunology (2017) 0.75
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Front Immunol (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology (2017) 0.75
Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans. Am J Pathol (2017) 0.75
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol (2007) 2.34
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
Tumor antigens. Annu Rev Immunol (1992) 1.41
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther (2008) 0.99
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol (2005) 2.51
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol (2006) 2.42
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 1.89
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol (2003) 1.72
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res (2012) 1.63
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother (2006) 1.57
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol (2002) 1.56
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 1.55
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging (2004) 1.54
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol (2006) 1.51
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol (2007) 1.27
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol (2003) 1.26
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs (2010) 1.22
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol (2006) 1.20
Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol (2004) 1.18
Molecular regulation of T-cell anergy. EMBO Rep (2008) 1.16
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med (2012) 1.16
Beta-catenin does not regulate memory T cell phenotype. Nat Med (2010) 1.13
Negative regulation of T-cell function by PD-1. Crit Rev Immunol (2004) 1.11
Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol (2006) 1.10
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs (2012) 1.09
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol (2005) 1.08
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood (2013) 1.07
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 1.03
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods (2007) 1.02
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A (2006) 1.01
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother (2008) 1.01
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation. J Immunol (2010) 0.99
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem (2003) 0.98
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol (2012) 0.97
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol (2004) 0.94
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol (2005) 0.92
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.92
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL. Eur J Immunol (2003) 0.92
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A (2009) 0.91
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res (2004) 0.90
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun (2003) 0.90
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol (2007) 0.89
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol (2013) 0.88
The composition of the microbiota modulates allograft rejection. J Clin Invest (2016) 0.88
Cancer immunotherapy. Curr Opin Immunol (2013) 0.87
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood (2007) 0.86
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol (2003) 0.85
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One (2011) 0.85
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol (2009) 0.85
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother (2005) 0.84
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res (2010) 0.83
Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Cytom (2008) 0.83
PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol (2014) 0.83
The host STING pathway at the interface of cancer and immunity. J Clin Invest (2016) 0.83
Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest (2016) 0.82
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol (2002) 0.82
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol (2013) 0.82
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma (2009) 0.82
Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma (2013) 0.82
T cell development and function in CrkL-deficient mice. Eur J Immunol (2003) 0.82
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs (2006) 0.81
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer (2003) 0.80
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med (2012) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol (2013) 0.79
Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy (2012) 0.79
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma (2010) 0.78
Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res (2005) 0.78
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol (2006) 0.78
Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol (2004) 0.78
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol (2009) 0.78
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother (2002) 0.78
Peripheral T-cell tolerance in hosts with acute myeloid leukemia. Oncoimmunology (2013) 0.78
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging (2014) 0.78
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol (2009) 0.77